Impact of epoetin alfa on clinical end points in patients with chronic renal failure: A meta-analysis

Kidney International

Volumn 65, Issue 3, 2004, Pages 757-767

  Jones, Michael ^b   Ibels, Lloyd ^b   Schenkel, Brad ^a   Zagari, Martin ^b  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b NONE

Author keywords

Anemia; Chronic renal failure; Epoetin alfa; Hospitalization; Meta analysis; Quality of life; Transfusion

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; META ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; REVIEW; TRANSFUSION;

EID: 1342343893     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00450.x     Document Type: Article

References (38)

1. BEUSTERIEN KM, NISSENSON AR, PORT FK, KELLY M, et al: The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 7:763-773, 1996
2. BRON D, MEULEMAN N, MASCAUX C: Biological basis of anemia [review]. Semin Oncol 28(Suppl 8):S1-S6, 2001
3. DELANO BG: Improvements in quality of life following treatment with rHuEPO in anemic hemodialysis patients. Am J Kidney Dis 14(Suppl 1):S14-S18, 1989
4. NISSENSON AR, FOR THE NATIONAL COOPERATIVE RHU ERYTHROPOIETIN STUDY GROUP: National cooperative rHu erythropoietin study in patients with chronic renal failure: A phase IV multicenter study. Am J Kidney Dis 18(Suppl 1):24-33, 1991
5. REVICKI DA, BROWN RE, FEENY DH, et al: Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 25:548-554, 1995
6. RIABOV SI, SHOSTKA GD, PETROVA NN, VASIL'EVA IA, et al: The effect of Recormon therapy on the quality of life of patients on hemodialysis treatment [in Russian; English abstract]. Ter Arkh 68:43-46, 1996
7. MORENO F, SANZ-GUAJARDO D, LOPEZ-GOMEZ JM, et al, FOR THE SPANISH COOPERATIVE RENAL PATIENTS QUALITY OF LIFE STUDY GROUP OF THE SPANISH SOCIETY OF NEPHROLOOY: Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. J Am Soc Nephrol 11:335-342, 2000
8. CANADIAN ERYTHROPOIETIN STUDY GROUP: Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 300:573-578, 1990
9. MUIRHEAD N, LAUPACIS A, WONG C: Erythropoietin for anaemia in haemodialysis patients: Results of a maintenance study (the Canadian Erythropoietin Study Group). Nephrol Dial Transplant 7:811-816, 1992
10. BIRKS JS, MELZER D: Mild and moderate Alzheimer's disease (Cochrane Review). The Cochrane Library, Issue 3, Oxford Update Software, 2000
11. BIRKS J, IAKOVIDOU V, TSOLAKI M: Rivastigmine for Alzheimer's Disease (Cochrane Review). The Cochrane Library, Issue 3, Oxford Update Software, 2000
12. DERSIMONIAN R, LAIRD N: Meta-analysis in clinical trials. Control Clin Trials 7:177-188, 1986
13. EGGER M, DAVEY SMITH G, SCHNEIDER M, et al: Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634, 1997
14. KARNOFSKY DA, BURCHENAL JH: The clinical evaluation of chemotherapeutic agents in cancer, in Evaluation of Chemotherapeutic Agents, edited by Macleod CM, New York, NY, Columbia University Press, 1949, pp 191-205
15. GUYATT GH, BOMBARDIER C, TUGWELL PX: Measuring disease-specific quality of life in clinical trials. Can Med Assoc J 134:889-895, 1986
16. BERGNER M, BOBITT RA, CARTER WB, et al: The sickness impact profile: development and final revision of a health-status measure. Med Care 19:787-805, 1981
17. HARRIS DC, CHAPMAN JR, STEWART JH, et al: Low dose erythropoietin in maintenance haemodialysis: Improvement in quality of life and reduction in true cost of haemodialysis. Aust N Z J Med 21:693-700, 1991
18. POWE NR, GRIFFITHS RI, WATSON AJ, et al: Effect of recombinant erythropoietin on hospital admissions, readmissions, length of stay, and costs of dialysis patients. J Am Soc Nephrol 4:1455-1465, 1994
19. ESCHBACH JW, ABDULHADI MH, BROWNE JK, et al: Recombinant human erythropoietin in anemic patients with end-stage renal disease: Results of a phase III multicenter clinical trial. Ann Intern Med 111:992-1000, 1989
20. PAGANINI EP, LATHAM D, ABDULHADI M. Practical considerations of recombinant human erythropoietin therapy. Am J Kidney Dis 14(Suppl 1):19-25, 1989
21. DUFF DR, GOLPER TA, SLOAN RS, et al: Low-dose recombinant human erythropoietin therapy in chronic hemodialysis patients. Am J Kidney Dis 18:60-64, 1991
22. SUNDAL E, BUSINGER J, KAPPELER A: Treatment of transfusion-dependent anaemia of chronic renal failure with recombinant human erythropoietin: A European multicentre study in 142 patients to define dose regimen and safety profile. Nephrol Dial Transplant 6:955-965, 1991
23. AUER J, SIMON G, STEVENS J, et al: Quality of life improvements in CAPD patients treated with subcutaneously administered erythropoietin for anemia. Perit Dial Int 12:40-42, 1992
24. MUIRHEAD N, CHURCHILL DN, GOLDSTEIN M, et al: Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease. Am J Nephrol 12:303-310, 1992
25. STEVENS ME, SUMMERFIELD GP, HALL AA, et al: Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease. BMJ 304:474-477, 1992
26. MORENO F, ARACIL FJ, PEREZ R, VALDERRABANO F: Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. Am J Kidney Dis 27:548-556, 1996
27. KURIYAMA S, TOMONARI H, YOSHIDA H, et al: Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77:176-185, 1997
28. OFSTHUN N, LABRECQUE J, LACSON E, et al: The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 63:1908-1914, 2003
29. LANGER CJ: Anaemia, fatigue and quality of life in advanced malignancy: Potential therapeutic role for epoetin. Erythropoiesis: New Dimensions in the Treatment of Anaemia 8:63-73, 1997
30. VARNEY SJ, GUEST JF. The annual cost of blood in the UK. J Transfusion Med 2003, in press
31. REMÁK E, HUTTON J, JONES M, ZAGARI M: Changes in cost-effectiveness over time: The case for epoetin alfa for renal replacement therapy patients in the UK. Eur J Health Econ 4:115-121, 2003
32. OBRADOR GT, ROBERTS T, ST PETER WL, et al: Trends in anemia at initiation of dialysis in the United States. Kidney Int 60:1875-1884, 2001
33. THACKER SB. Meta-analysis: A quantitative approach to research integration. JAMA 259:1685-1689, 1988
34. CHALMERS TC, LAU J. Meta-analytic stimulus for changes in clinical trials. Stat Methods Med Res 2:161-172, 1993
35. BEGG CB. The role of meta-analysis in monitoring clinical trials. Stat Med 15:1299-1307, 1996
36. IOANNIDIS JP, SCHMID CH, LAU J. Meta-analysis in hematology and oncology. Hematol Oncol Clin North Am 14:973-991, 2000
37. IOANNIDIS JPA, CAPPELLERI JC, LAU J. Meta-analyses and large randomized, controlled trials [letter]. N Engl J Med 338:59, 1998
38. LAU J, IOANNIDIS JP, SCHMID CH. Summing up evidence: One answer is not always enough. Lancet 351:123-127, 1998